Avidity Biosciences Inc’s filing revealed that its Director LEVIN ARTHUR A unloaded Company’s shares for reported $0.11 million on Apr 19 ’24. In the deal valued at $22.82 per share,5,000 shares were sold. As a result of this transaction, LEVIN ARTHUR A now holds 14,830 shares worth roughly $0.39 million.
Then, LEVIN ARTHUR A sold 20,000 shares, generating $542,214 in total proceeds. Upon selling the shares at $27.11, the Director now owns 253,872 shares.
Before that, Boyce Sarah sold 28,000 shares. Avidity Biosciences Inc shares valued at $734,919 were divested by the President and CEO at a price of $26.25 per share. As a result of the transaction, Boyce Sarah now holds 112,117 shares, worth roughly $2.95 million.
BofA Securities initiated its Avidity Biosciences Inc [RNA] rating to a Buy in a research note published on May 03, 2024; the price target was $40. A number of analysts have revised their coverage, including Cantor Fitzgerald’s analysts, who began to cover the stock in mid March with a ‘”an Overweight”‘ rating. Evercore ISI also remained covering RNA and has increased its forecast on May 22, 2023 with a “an Outperform” recommendation from previously “an In-line” rating. Evercore ISI revised its rating on March 31, 2023. It rated RNA as “an In-line” which previously was an “an Outperform”.
Price Performance Review of RNA
On Monday, Avidity Biosciences Inc [NASDAQ:RNA] saw its stock fall -0.45% to $26.33. Over the last five days, the stock has gained 6.60%. Avidity Biosciences Inc shares have risen nearly 190.94% since the year began. Nevertheless, the stocks have risen 135.09% over the past one year. While a 52-week high of $27.66 was reached on 04/03/24, a 52-week low of $4.82 was recorded on 01/02/24. SMA at 50 days reached $23.28, while 200 days put it at $12.12. A total of 0.55 million shares were traded, compared to the trading of 0.56 million shares in the previous session.
Levels Of Support And Resistance For RNA Stock
The 24-hour chart illustrates a support level at 25.76, which if violated will result in even more drops to 25.20. On the upside, there is a resistance level at 26.87. A further resistance level may holdings at 27.42. The Relative Strength Index (RSI) on the 14-day chart is 61.43, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at 1.49, which suggests price will go up in the next trading period. Percent R suggests that price movement has been bullish at 19.80%. Stochastics %K at 77.79% indicates the stock is a holding.
The most recent change occurred on July 20, 2022 when Chardan Capital Markets began covering the stock and recommended ‘”a Buy”‘ rating along with a $29 price target.
